U.S., Dec. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07293884) titled 'N- Acetylcysteine in Airway Clearance in Broncheictasis' on Nov. 26.
Brief Summary: It has been deduced that reducing the production of mucus or improving the clearance of sputum in the airway is the key to enhance the therapeutic efficacy for bronchiectasis . Mucoactive drugs are commonly used to clear the airway in mucus hypersecretion diseases. Currently, investigators have found that N-acetylcysteine (NAC), an effective mucolytic agent, not only reduces the viscosity and elasticity of sputum, but it also has anti-inflammatory and antioxidant activity.
Additionally, the Spanish guidelines on the treatment of bronchiectasis indic...